PMID- 32769900
OWN - NLM
STAT- MEDLINE
DCOM- 20200824
LR  - 20221005
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 99
IP  - 32
DP  - 2020 Aug 7
TI  - Hypoglycemic agents for non-alcoholic fatty liver disease with type 2 diabetes 
      mellitus: A protocol for systematic review and network meta-analysis.
PG  - e21568
LID - 10.1097/MD.0000000000021568 [doi]
LID - e21568
AB  - BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the most common cause of 
      chronic liver disease in Western countries, and strongly associated with type 2 
      diabetes mellitus (T2DM). Several studies have shown that hypoglycemic agents are 
      effective for NAFLD combined with T2DM. However, there is still controversy over 
      which hypoglycemic agent is the best for NAFLD combined with T2DM patients. 
      OBJECTIVE: To systematically evaluate the efficacy and safety of hypoglycemic 
      agents in NAFLD combined with T2DM patients. METHODS: A comprehensive electronic 
      search will be conducted by searching Web of Science, PubMed, EMBASE, Cochrane 
      Central Register of Controlled Trials, Clinical Trials and Chinese Biomedical 
      Medicine. All randomized controlled trials of hypoglycemic agents interventions 
      for NAFLD combined with T2DM will be identified. Two reviewers independently 
      screened and evaluated each included study and extracted the outcome indexes. 
      ADDIS 1.16.8 software will be used for the network meta-analysis and STATA 14 
      software will be used for drawing network evidence plots and funnel plots. 
      CONCLUSION: This network meta-analysis will provide stronger evidence for the 
      efficacy and safety of hypoglycemic agents in the treatment of NAFLD combined 
      with T2DM, and provide a reference for clinical application. PROTOCOL 
      REGISTRATION NUMBER: INPLASY202070016.
FAU - Liu, Su-Tong
AU  - Liu ST
AD  - Henan University of Chinese Medicine.
FAU - Su, Kai-Qi
AU  - Su KQ
AD  - Henan University of Chinese Medicine.
FAU - Zhang, Li-Hui
AU  - Zhang LH
AD  - Henan University of Chinese Medicine.
AD  - Department of Gastroenterology, The First Affiliated Hospital of Henan University 
      of Chinese Medicine, Zhengzhou, Henan, PR China.
FAU - Liu, Ming-Hao
AU  - Liu MH
AD  - Henan University of Chinese Medicine.
AD  - Department of Gastroenterology, The First Affiliated Hospital of Henan University 
      of Chinese Medicine, Zhengzhou, Henan, PR China.
FAU - Zhao, Wen-Xia
AU  - Zhao WX
AUID- ORCID: 0000-0001-6666-9469
AD  - Henan University of Chinese Medicine.
AD  - Department of Gastroenterology, The First Affiliated Hospital of Henan University 
      of Chinese Medicine, Zhengzhou, Henan, PR China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - *Clinical Protocols
MH  - Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology/*therapeutic use
MH  - Meta-Analysis as Topic
MH  - Non-alcoholic Fatty Liver Disease/*drug therapy/physiopathology
MH  - Systematic Reviews as Topic
PMC - PMC7593046
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2020/08/10 06:00
MHDA- 2020/08/25 06:00
PMCR- 2020/08/07
CRDT- 2020/08/10 06:00
PHST- 2020/08/10 06:00 [entrez]
PHST- 2020/08/10 06:00 [pubmed]
PHST- 2020/08/25 06:00 [medline]
PHST- 2020/08/07 00:00 [pmc-release]
AID - 00005792-202008070-00041 [pii]
AID - MD-D-20-06428 [pii]
AID - 10.1097/MD.0000000000021568 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2020 Aug 7;99(32):e21568. doi: 10.1097/MD.0000000000021568.